On June 2, 2024, Caribou issued a press release announcing that it had “presented updated clinical data from the ongoing ANTLER Phase 1 trial that [purportedly] indicates a single dose of CB-010 . . .

The majority are in the very early preclinical stage of development, but applications for regulatory approval have been ...

An FDA safety announcement regarding labeling changes for the commonly used oncology drugs capecitabine and 5-fluorouracil highlights a risk of dihydropyrimidine dehydrogenase deficiency, which can ...

Bristol Myers on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Breyanzi for the treatment of adults with relapsed or refractory ...

The Economic Survey 2024-25 says on a global pedestal, India has successfully established itself as one of the top 20 medical ...

The Economic Survey 2024-25 emphasises the need for increased innovation, new drug development, and biopharmaceutical ...

There is a need to focus on innovation, new drug development and biopharmaceuticals as spending on research and development ...

HonorHealth announced the creation of its new international Center for Translational Science. Sanofi said it will repurchase $5.2 billion of stock and grow profits faster this year as the drugmaker ...

Do you remember the fall of your high school senior year—the college essays, endless applications, forms, decisions, the big ...

Bristol-Myers Squibb (NYSE:BMY), a global biopharmaceutical company with a market capitalization of nearly $120 billion, finds itself at a critical juncture as it navigates a complex landscape of ...

VectorBuilder's partner, Ucello, announced that its CD19-targeting umbilical cord blood-derived allogeneic CAR-T cell therapy ...

The early stage company is developing a new approach to gene editing to treat rare genetic diseases. It does this using mRNA, ...